A living WHO guideline on drugs for covid-19 A Agarwal, BJ Hunt, M Stegemann, B Rochwerg, F Lamontagne, ... bmj 370, 2020 | 1051* | 2020 |
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries H Getahun, A Matteelli, I Abubakar, MA Aziz, A Baddeley, D Barreira, ... European Respiratory Journal 46 (6), 1563-1576, 2015 | 744 | 2015 |
Corona virus disease 2019 D Handayani, DR Hadi, F Isbaniah, E Burhan, H Agustin Jurnal Respirologi Indonesia 40 (2), 119-129, 2020 | 375 | 2020 |
Pedoman nasional pengendalian tuberkulosis RI Kemenkes Jakarta: kementerian kesehatan RI, 2014 | 360 | 2014 |
Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study H Surendra, IRF Elyazar, BA Djaafara, LL Ekawati, K Saraswati, V Adrian, ... The Lancet Regional Health–Western Pacific 9, 2021 | 231 | 2021 |
Pedoman tatalaksana COVID-19 E Burhan | 221 | 2020 |
Pneumonia covid-19 diagnosis & penatalaksanaan di Indonesia E Burhan, F Isbaniah, AD Susanto, Y Yoga, A Tjandra, T Sugiri, ... Jakarta: Perhimpunan Dokter Paru Indonesia, 1-49, 2020 | 176 | 2020 |
Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: a randomized controlled trial IH Dilogo, D Aditianingsih, A Sugiarto, E Burhan, T Damayanti, ... Stem cells translational medicine 10 (9), 1279-1287, 2021 | 151 | 2021 |
A living WHO guideline on drugs to prevent covid-19 F Lamontagne, M Stegemann, A Agarwal, T Agoritsas, R Siemieniuk, ... bmj 372, 2021 | 146 | 2021 |
Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients E Burhan, C Ruesen, R Ruslami, A Ginanjar, H Mangunnegoro, ... Antimicrobial agents and chemotherapy 57 (8), 3614-3619, 2013 | 124 | 2013 |
A living WHO guideline on drugs for covid-19 R Siemieniuk, B Rochwerg, T Agoritsas, F Lamontagne, YS Leo, ... BMJ: British Medical Journal 370, 1-14, 2020 | 123 | 2020 |
Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial South East Asia Infectious Disease Clinical Research Network Bmj 346, 2013 | 122 | 2013 |
Treatment strategy for rifampin-susceptible tuberculosis NI Paton, C Cousins, C Suresh, E Burhan, KL Chew, VB Dalay, Q Lu, ... New England Journal of Medicine 388 (10), 873-887, 2023 | 115 | 2023 |
Pedoman tatalaksana COVID-19 edisi 4 E Burhan, AD Susanto, SA Nasution, E Ginanjar, CW Pitoyo, A Susilo, ... Jakarta: PDPI, PERKI, PAPDI, PERDATIN, IDAI 2 (1), 2020 | 108 | 2020 |
Molecular diagnosis of tuberculosis F Nurwidya, D Handayani, E Burhan, F Yunus Chonnam medical journal 54 (1), 1-9, 2018 | 98 | 2018 |
Body mass index predictive of sputum culture conversion among MDR-TB patients in Indonesia FA Putri, E Burhan, A Nawas, PZ Soepandi, DK Sutoyo, H Agustin, ... The International journal of tuberculosis and lung disease 18 (5), 564-570, 2014 | 98 | 2014 |
COVID‑19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study ICCG 1062 ISARIC Clinical Characterisation Group 49, 889-905, 2021 | 90* | 2021 |
Effects of introducing Xpert MTB/RIF on diagnosis and treatment of drug-resistant tuberculosis patients in Indonesia: a pre-post intervention study SC Van Kampen, NH Susanto, S Simon, SD Astiti, R Chandra, E Burhan, ... PloS one 10 (6), e0123536, 2015 | 82 | 2015 |
Pedoman pencegahan dan pengendalian coronavirus disease (covid-19) A Sugihantono, E Burhan, AD Susanto, T Damayanti, WH Wiyono, ... Jakarta Selatan: Kemenkes RI, 2020 | 79 | 2020 |
Protokol tatalaksana COVID-19 E Burhan, AD Susanto, SA Nasution, E Ginanjar, CW Pitoyo, A Susilo, ... Jakarta: PDPI, PERKI, PAPDI, PERDATIN, IDAI 50, 2020 | 67 | 2020 |